Therefore, our real-world ATLAS cohort study was conducted to evaluate the preliminary activity of HER2-targeted TKIs for heterogeneous HER2 missense alterations in metastatic NSCLC, aiming to reveal their discrepant structures. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.